Zacks Investment Research on MSN10h
All You Need to Know About Exelon (EXC) Rating Upgrade to Buy
Exelon (EXC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most ...
Evaxion announces business update and full year 2024 financial results
COPENHAGEN, Denmark, April 1, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business ...